Video

Recent Updates in PARP Inhibitor Indications for Ovarian Cancer

Author(s):

Bradley J. Monk, MD, FACS, FACOG,Robert L. Coleman, MD, FACOG, FACS

Dr Robert Coleman reviews data from the ARIEL-4 trial on rucaparib in recurrent ovarian cancer, sparking a discussion on PARP inhibitor use.

Related Videos
Kathleen N. Moore, MD, MS
Kathleen N. Moore, MD, MS
Jennifer Scalici, MD
Related Content
Ovarian Cancer
December 20th 2024

Addition of Dostarlimab to Chemo and Niraparib Maintenance Boosts PFS in Advanced Ovarian Cancer

Vadim Gushchin, MD; Teresa Diaz-Montes, MD, MPH, FACOG
April 20th 2023

Gushchin and Diaz-Montes Describe QOL Outcomes After Cytoreduction and HIPEC in Ovarian Cancer

IMNN-01 Plus Perioperative Chemotherapy Maintains OS Benefit in Newly Diagnosed Advanced Ovarian Cancer
December 10th 2024

IMNN-001 Plus Perioperative Chemotherapy Maintains OS Benefit in Newly Diagnosed Advanced Ovarian Cancer

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer
July 18th 2022

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer

Ovarian Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
December 9th 2024

Pembrolizumab/Chemo, Followed by Olaparib Maintenance, Boosts PFS in Advanced Ovarian Cancer

Premal Thaker, MD, MS
December 2nd 2024

IMNN-001 Plus Chemo Data Highlight Potential to Fill Unmet Need in Ovarian Cancer